GlassScriptPhysician profile
Peter Jeffrey Vance
NPI 1740243856
$1,646.27
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,210 · 2020: $140 · 2021: $221 · 2023: $44.45 · 2024: $30.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $74.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $74.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $301.13 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $189.19 | 2019-2021 | |
| Comsort, INC | $150.00 | 2019 | |
| Pfizer INC. | $135.13 | 2019 | |
| Stryker Corporation | $112.20 | 2019 | |
| Amgen INC. | $78.98 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $75.15 | 2019 | |
| Glaxosmithkline, LLC. | $58.84 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.51 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $55.04 | 2019 | |
| Janssen Pharmaceuticals, INC | $49.46 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $42.29 | 2019-2023 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.27 | 2019-2020 | |
| Lilly USA, LLC | $35.72 | 2019-2020 | |
| Exact Sciences Corporation | $30.29 | 2024 | Cologuard Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.08 | 2019 | |
| Amarin Pharma, INC. | $29.09 | 2019-2020 | |
| Alkermes, INC. | $25.70 | 2019 | |
| Astellas Pharma US INC | $23.97 | 2019 | |
| Merck Sharp & Dohme LLC | $21.56 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $19.10 | 2019 | |
| Alfasigma USA, INC. | $16.63 | 2020 | |
| Shire North American Group INC | $15.39 | 2019 | |
| Phadia US INC. | $15.00 | 2023 | Immunocap |
| Horizon Therapeutics Plc | $13.20 | 2019 | |
| Allergan, INC. | $13.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Vance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.